Q1 2024 EPS Estimates for R1 RCM Inc. Reduced by Leerink Partnrs (NASDAQ:RCM)

R1 RCM Inc. (NASDAQ:RCM - Free Report) - Investment analysts at Leerink Partnrs decreased their Q1 2024 earnings estimates for shares of R1 RCM in a research note issued to investors on Monday, April 29th. Leerink Partnrs analyst M. Cherny now anticipates that the healthcare provider will post earnings per share of $0.02 for the quarter, down from their previous forecast of $0.03. Leerink Partnrs currently has a "Outperform" rating on the stock. The consensus estimate for R1 RCM's current full-year earnings is ($0.05) per share. Leerink Partnrs also issued estimates for R1 RCM's Q4 2024 earnings at $0.05 EPS and FY2026 earnings at $0.42 EPS.

Several other research analysts also recently commented on RCM. SVB Leerink assumed coverage on shares of R1 RCM in a report on Monday, February 26th. They issued an "outperform" rating and a $14.00 price target for the company. Canaccord Genuity Group cut their price target on shares of R1 RCM from $17.00 to $16.00 and set a "buy" rating for the company in a report on Wednesday, March 20th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $20.00 price objective on shares of R1 RCM in a report on Wednesday, April 10th. Barclays reaffirmed an "equal weight" rating and set a $14.00 price objective on shares of R1 RCM in a report on Wednesday, February 28th. Finally, Evercore ISI reaffirmed an "in-line" rating and set a $16.00 price objective (up from $12.00) on shares of R1 RCM in a report on Wednesday, February 28th. Five research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $16.87.

R1 RCM Price Performance

RCM traded up $0.09 on Thursday, hitting $12.45. The company's stock had a trading volume of 961,568 shares, compared to its average volume of 3,520,569. The company's 50 day simple moving average is $12.92 and its 200-day simple moving average is $11.42. The company has a quick ratio of 1.83, a current ratio of 1.83 and a debt-to-equity ratio of 0.57. R1 RCM has a 12 month low of $8.87 and a 12 month high of $18.70.

Insider Buying and Selling

In other R1 RCM news, President John M. Sparby sold 10,046 shares of the business's stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $14.33, for a total value of $143,959.18. Following the transaction, the president now owns 265,986 shares in the company, valued at $3,811,579.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 36.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On R1 RCM

Hedge funds have recently modified their holdings of the company. Headlands Technologies LLC purchased a new position in shares of R1 RCM during the third quarter valued at about $36,000. Van ECK Associates Corp boosted its stake in R1 RCM by 28.5% during the third quarter. Van ECK Associates Corp now owns 5,097 shares of the healthcare provider's stock worth $77,000 after acquiring an additional 1,130 shares in the last quarter. ANTIPODES PARTNERS Ltd boosted its stake in R1 RCM by 429.5% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,623 shares of the healthcare provider's stock worth $59,000 after acquiring an additional 4,561 shares in the last quarter. Salem Investment Counselors Inc. bought a new stake in R1 RCM during the fourth quarter worth about $61,000. Finally, Fox Run Management L.L.C. bought a new stake in R1 RCM during the third quarter worth about $189,000. Hedge funds and other institutional investors own 61.10% of the company's stock.

R1 RCM Company Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.